Literature DB >> 18602031

Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content.

Victor V Pleshkan1, Tatyana V Vinogradova, Eugene D Sverdlov.   

Abstract

Prominin 1 (PROM1, CD133) is a unique transmembrane glycoprotein encoded by the PROM1 gene. It is a cell surface marker of various stem cells including hematopoietic, prostatic epithelial, pancreatic, leukemic, liver cancer, and colorectal cancer stem cells. Here, we studied tissue specificity of PROM1 transcription isoforms and the methylation level of its two main promoters (P1 and P2) in different human cell lines. Only transcripts lacking the 4th exon (the CD133.s1 form) were expressed in cell lines studied. Moreover, these transcripts, if sufficiently abundant, were initiated simultaneously and independently from both promoters P1 and P2. In cell lines with low levels of the total PROM1 transcript, the transcription was likely initiated from other promoters. Promoter P1 was hypermethylated in all cell lines under study, and therefore, methylation can hardly play an important role in its regulation. In contrast, the methylation of promoter P2 was tissue specific, and hypomethylation of this promoter is probably necessary but not sufficient for efficient transcription of the PROM1 gene. Therefore, we report an unusual instance of different mechanisms of transcription activity regulation for two closely located promoters of the same gene.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602031     DOI: 10.1016/j.bbagrm.2008.06.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.

Authors:  You-Kyung Jeon; Sung-Hee Kim; Seung-Ho Choi; Kyung-Hee Kim; Byong-Chul Yoo; Ja-Lok Ku; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

2.  Epigenetic reprogramming modulates malignant properties of human liver cancer.

Authors:  Chiara Raggi; Valentina M Factor; Daekwan Seo; Agnes Holczbauer; Matthew C Gillen; Jens U Marquardt; Jesper B Andersen; Marian Durkin; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2014-05-01       Impact factor: 17.425

3.  Expression of the FAP gene in non-fibroblast human cell lines. Development of cancer-associated fibroblast models.

Authors:  D V Tyulkina; V V Pleshkan; I V Alekseenko; M R Kopantseva; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2016-11-06       Impact factor: 0.788

4.  Extended extraocular phenotype of PROM1 mutation in kindreds with known autosomal dominant macular dystrophy.

Authors:  Francesca I Arrigoni; Mar Matarin; Pamela J Thompson; Michel Michaelides; Michelle E McClements; Elizabeth Redmond; Lindsey Clarke; Elizabeth Ellins; Saifullah Mohamed; Ian Pavord; Nigel Klein; David M Hunt; Anthony T Moore; Julian Halcox; Sanjay M Sisodiya
Journal:  Eur J Hum Genet       Date:  2010-09-22       Impact factor: 4.246

5.  Activity of the upstream component of tandem TERT/survivin promoters depends on features of the downstream component.

Authors:  Irina V Alekseenko; Victor V Pleshkan; Eugene P Kopantzev; Elena A Stukacheva; Igor P Chernov; Tatyana V Vinogradova; Eugene D Sverdlov
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

6.  Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.

Authors:  Xing Wu; Fenlang Wu; Dongwen Xu; Tao Zhang
Journal:  J Neurooncol       Date:  2016-01-12       Impact factor: 4.130

7.  CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.

Authors:  Khalilullah Mia-Jan; So Young Jung; Ik-Yong Kim; Sung Soo Oh; EunHee Choi; Sei Jin Chang; Tae Young Kang; Mee-Yon Cho
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

8.  The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers.

Authors:  Kyung-Jin Min; Kyeong A So; Yung-Taek Ouh; Jin-Hwa Hong; Jae-Kwan Lee
Journal:  J Ovarian Res       Date:  2012-10-15       Impact factor: 4.234

9.  A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells.

Authors:  Ramakrishna Sompallae; Oliver Hofmann; Christopher A Maher; Craig Gedye; Andreas Behren; Morana Vitezic; Carsten O Daub; Sylvie Devalle; Otavia L Caballero; Piero Carninci; Yoshihide Hayashizaki; Elizabeth R Lawlor; Jonathan Cebon; Winston Hide
Journal:  Front Genet       Date:  2013-10-29       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.